Royalty Report: Drugs, Disease, Therapeutic – Collection: 29275

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Ophthalmological
  • Pharmaceuticals
  • Delivery
  • Diabetes Treatment
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29275

License Grant
The Company, who develops miniaturized, injectable, drug delivery systems and the Licensee, amended and restated their February 2005 License and collaboration agreement relating to Iluvien, the company’s Phase III investigative treatment for diabetic macular edema, and certain other products.
License Property
Diabetic macular edema is swelling of the retina in diabetes mellitus due to leaking of fluid from blood vessels within the macula.

The macula is the central portion of the retina, a small area rich in cones, the specialized nerve endings that detect color and upon which daytime vision depends.

Field of Use
Collaboration Field shall mean the treatment and prevention of eye diseases in humans; provided, however, that the treatment and prevention of [*] is excluded from the Collaboration Field.

IPSCIO Record ID: 234135

License Grant
Prior to entering into the New Collaboration Agreement, the Company held the worldwide license from Licensor for the use of Licensor’s proprietary insert technology for the treatment of all ocular diseases other than uveitis. The New Collaboration Agreement expands the license to include uveitis, including NIPU, in Europe, the Middle East and Africa and allows the Company to also pursue an indication for posterior uveitis for ILUVIEN in those territories.  The New Collaboration Agreement converts the Company’s obligation to share 20% of its net profits to a royalty payable on global net revenues of ILUVIEN.
License Property
ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).

Uveitis is an inflammatory disease of the uveal tract, which is comprised of the iris, ciliary body and choroid, that can lead to severe vision loss and blindness.

Diabetic Macular Edema (DME) is an accumulation of fluid in the macula—part of the retina that controls our most detailed vision abilities—due to leaking blood vessels. In order to develop DME, you must first have diabetic retinopathy. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision impairment.

Field of Use
This agreement pertains to the drug industry relating for the treatment of vision impairment.

IPSCIO Record ID: 197910

License Grant
The Licensor announced an amendment of its exclusive license and collaboration agreement with Licensee that grants Licensee rights to Licensor’s Durasertâ„¢ three-year treatment for posterior segment uveitis (Durasert) in Europe, the Middle East and Africa (EMEA).  With this license, Licensee plans to pursue a secondary indication for ILUVIEN for posterior segment uveitis in EMEA, which could accelerate the uveitis indication approval as well as commercialization. Licensor retains commercialization rights for posterior segment uveitis in all other countries, including the United States. The amended agreement also modifies the companies’ existing global licensing agreement for ILUVIEN for the treatment of diabetic macular edema (DME).
License Property
ILUVIEN is for the treatment of posterior segment uveitis.   ILUVIEN®, a micro-insert for diabetic macular edema.

Posterior segment uveitis is a chronic, non-infectious inflammatory disease affecting the posterior segment of the eye, often involving the retina, which is believed to be a leading cause of blindness in the developed and developing countries. It affects people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision loss and blindness. In the U.S. and EU, posterior uveitis affects approximately 200,000 people, annually. Today, patients with posterior uveitis are typically treated with systemic steroids, but over time frequently develop serious side effects that can limit effective dosing. Patients then often progress to steroid-sparing therapy with systemic immune suppressants or biologics, which themselves can have severe side effects including an increased risk of cancer.

Field of Use
This agreement pertains to the drug industry relating to products for treating eye diseases.

IPSCIO Record ID: 200867

License Grant
Licensor hereby grants to Licensee an exclusive transferable worldwide, sublicensable right and license, under the Licensed Intellectual Property, to Develop, make, have made, Commercialize, use, sell, offer for sale, have sold, import, export and otherwise exploit Licensed Products in the Field. Without limiting the foregoing, the foregoing license includes
(a) Any use or purpose in the Field, including without limitation, the diagnosis, treatment, amelioration and/or prevention of any human or animal disease, disorder or condition.
License Property
Licensor owns certain patents and know how and wishes to obtain a development and commercialization partner for its Plasma Kallikrein Inhibitor program (“PKI Program”);

PKI Program means the Plasma Kallikrein Inhibitor program for diabetic macular edema and other human therapeutic indications.  Diabetic Macular Edema (DME) is an accumulation of fluid in the macula—part of the retina that controls our most detailed vision abilities—due to leaking blood vessels. In order to develop DME, you must first have diabetic retinopathy.

Field of Use
“Field” means the diagnosis, treatment, prevention or amelioration of human and animal diseases.

This agreement pertains to the drug industry relating to diabetes.

IPSCIO Record ID: 297723

License Grant
Pursuant to the License Agreement, the Licensor has granted an exclusive license to the Hong Kong Licensee to develop, distribute, promote, market and commercialize XIPERE, subject to specified exceptions in the Territory.
License Property
XIPERE, is proprietary suspension of the corticosteroid triamcinolone acetonide.  The formulated product is for administration to the back of the eye, using the Licensor’s proprietary SCS Microinjector, the device.
Field of Use
The patented technology is designed to deliver drug to the suprachoroidal space located between the choroid and the outer protective layer of the eye, known as the sclera. Suprachoroidal injection enables the rapid and adequate dispersion of medicine to the back of the eye, offering the potential for the medicine to act longer and minimize harm to the surrounding healthy parts of the eye.

The field of use is for the treatment of macular edema associated with uveitis.

Uveitis is a form of eye inflammation. It affects the middle layer of tissue in the eye wall (uvea). Uveitis (u-vee-I-tis) warning signs often come on suddenly and get worse quickly. They include eye redness, pain and blurred vision. The condition can affect one or both eye. Macular edema is the build-up of fluid in the macula, an area in the center of the retina.

IPSCIO Record ID: 2377

License Grant
The Company hereby grants to the Licensee exclusive rights to register, import, market, sell and distribute the Products in the Territory.
License Property
The Company has developed among other things certain proprietary technology relating to non-surgical therapeutic ophthalmic systems

Products refers to Vitrase(TM) and Corneaplasty, certain proprietary technology relating to non-surgical therapeutic ophthalmic systems.

We are developing Vitrase, a proprietary formulation of hyaluronidase, for treatment of severe vitreous hemorrhage, a sight threatening condition, and diabetic retinopathy, the leading cause of adult blindness in the United States.  Vitrase is currently in two Phase III clinical trials for treatment of severe vitreous hemorrhage. We are also conducting a pilot Phase IIa clinical trial of Vitrase in Mexico for treatment of diabetic retinopathy.  Vitreous hemorrhage.  A vitreous hemorrhage occurs when retinal blood vessels rupture and bleed into the vitreous humor, the clear, gel-like substance that fills the back of the eye between the lens and the retina.  The blood from the hemorrhage can obscure vision and prevent ophthalmologists from seeing into the eye to diagnose or treat the cause of the hemorrhage.  The only current treatment options are a watchful waiting period, during which no medical treatment is provided in the hope that the hemorrhage will clear on its own, and an invasive surgical procedure to remove the blood filled vitreous humor from the eye.  Vitrase, when injected into the vitreous humor, causes the vitreous humor to liquefy and promotes clearance of vitreous hemorrhage.  Based on market research we commissioned in February 1999, we believe that approximately one million cases of vitreous hemorrhage occur each year in the United States, Europe and Japan and that approximately half of these cases are candidates for treatment using Vitrase.

Field of Use
The field of use apply to the treatment of the eye.

IPSCIO Record ID: 26094

License Grant
The Licensor hereby granted to the Licensee a royalty-bearing, exclusive worldwide right and license, with the right to grant sublicenses, for Cytokine Modulator (CM) as a therapeutic drug containing a single active pharmaceutical ingredient or two or more active pharmaceutical ingredients where no component of the CM is tacrolimus, cyclosporine, ISAtx24, Rapamycin (Sirolimus), Pimecrolimus, Everolimus, another calcineurin inhibitor or a corticosteroid. Subject to the terms and conditions of this Agreement, the Licensor shall grant the Licensee a right of reference to the Licensor Generated Data to Exploit Licensed Products in the Licensed Combination Field.
License Property
BOE Disease means the following diseases Wet Age-related Macular Degeneration; Dry Age-related Macular Degeneration; Posterior uveitis (chorioentinitis); Retinitis Pigmentosa; Retinal Vein Occlusion; Retinal detachment; Retinal Artery Occlusion; Proliferative diabetic retinopathy; Post-operative inflammation; Persistant Macular Edema; Neovascular diseases involving the retina or uveal tract such as neovascular glaucoma, neovascularization following a combined vitrectomy and lensectomy, neovascularization of the optic nerve, and neovascularization due to penetration of the eye or contusive ocular injury; Inflammation due to ocular trauma; Open-angle glaucoma; Closed-angle glaucoma; Exudative macular edema; Diabetic Retinopathy; Diabetic Macular Edema; Cystoid macular edema; Chronic posterior uveitis; Allograft rejection; Behcet's syndrome; Chorioiditis; Crystalline retinopathy; Optic neurtitis; Proliferative sickle cell retinopathy; Proliferative vitreoretinopathy; Retinopathy of prematurity; Vitreitis; Temporal arteritis; Fuchs' Dystrophy; Dacryocystitis; Giant cell arteritis; Sympathetic ophthalmia; Pars planitis; Pan Uveitis; and all other similar diseases as agreed to by the Parties.
Field of Use
Licensee has certain proprietary in vitro and in vivo models of ophthalmic diseases, and clinical expertise in developing ophthalmic therapeutics.  Collaboration Combination Field means use of a Collaboration Combination by Local Administration to treat the diseases.

IPSCIO Record ID: 261

License Grant
Licensor hereby grants to Licensee and Licensee hereby accepts a non-exclusive license under the Licensed Patents for the Term of this Agreement to
(i) make and have made Licensed Product in the Territory solely for use or sale in the Field in the Territory, and to export Licensed Product that is initially made in bulk or other non-finished form in the Territory solely for the purpose of converting such Licensed Product to filled and/or finished form outside the Territory for reimportation into the Territory.
License Property
Licensed Product shall mean aflibercept, which is being sold in the Field in the Territory under the trade name Eyleaâ„¢ (aflibercept) as of the Effective Date, and any pharmaceutical formulation containing aflibercept that is intended for use in the Field in the Territory.

Licensed Patents shall mean (i) U.S. Patent Nos. 5,952,199; 6,100,071; 6,383,486; 6,897,294; and 7,771,721.

Field of Use
Field shall mean and be limited to the prevention or treatment of eye diseases and eye disorders in a human through the administration of Licensed Product to the eye, (including, but not limited to, the prevention or treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and/or myopic choroidal neovascularization in a human).

IPSCIO Record ID: 245932

License Grant
Exclusive License Grants. Licensor hereby grants to Licensee the following licenses

(a) an exclusive license (even as to Licensor) in the Territory under the Licensor Patent Rights, and Program Patent Rights to research, develop, make, have made, use, offer to sell, sell, have sold, import and export the Products in the Field;
  
(b) an exclusive license (even as to Licensor) in the Territory under the Licensor Know-How, the Licensor Program Know-How, and Licensor’s rights in Joint Program Know-How to research, develop, make, have made, use, offer to sell, sell, have sold, import and export the Products in the Field; and

(c) an exclusive license (even as to Licensor) in the Territory under the Licensor Technology to research, develop, make, have made, use, offer to sell, sell, have sold, import and export the Surgical Instruments solely for use with, or in connection with the sale of, the Products in the Field.

Notwithstanding the license grants set forth above, Licensor shall retain those rights under the Licensor Technology that are necessary to perform Licensor’s obligations under the Research Program and the Feasibility Studies in accordance with Agreement and to manufacture and supply clinical supplies and commercial supply of Product to Licensee and the scale up and transfer of manufacturing capabilities to Licensee in accordance with this Agreement and the Supply Agreement.

Non-Exclusive License Grant. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee a non-exclusive, royalty-free license in the Territory under the Licensor Program Technology, for any and all uses, including without limitation, to research, develop, make, have made, use, offer to sell, sell, have sold, import and export a product other than the Products.

License Property
Product(s) shall mean TA Product(s), [KDRProduct(s)], Other [Target] Product(s), or Combination Product(s), individually or collectively, unless otherwise specified that is in final form (a) for sale by prescription, over-the-counter or any other method, or (b) for administration in a Clinical Trial or post-Marketing Authorization clinical trial.

TA Product shall mean the I-vation Platform incorporating a TA Compound as an active ingredient (which shall include without limitation the I-vation TA Product) and, for the purposes of Sections 5.2 through 5.6, that is in final form (i) for sale by prescription, over-the-counter or any other method, or (ii) for administration in a Clinical Trial or post-Marketing Authorization clinical trial.

I-vation Platform shall mean the Intravitreal Implant, together with the polymers applied as a coating thereto, for the purpose of containing and delivering sustained release of one or more active ingredients or therapeutic agents into the vitreous chamber of the eye, and any Improvements thereto,

Target shall mean a distinct, primary molecular target.

Surgical Instruments shall mean the Insertion Tool and/or the Extraction Tool, and any Improvements thereto.

The I-vation Intravitreal Implant is a drug delivery system capable of delivering a variety of drugs on a sustained release basis for well over a year, can be implanted in a minimally invasive procedure, and may be removed once the drug has been fully released. Currently, the majority of treatments being developed for AMD and DME require repeated injections into the eye, often with a suboptimal drug dosing profile. Replacing multiple injections with a single implant providing long-term, controlled drug release could represent a significant advance in therapeutic treatment, including improved patient compliance, reduced side effects and greater efficacy.

I-vation TA (a version of the I-vation implant formulated with the steroid triamcinolone acetonide) is being studied in a Phase I human clinical trial called STRIDE (Sustained Triamcinolone Release for Inhibition of Diabetic Macular Edema). The trial is assessing the safety and tolerability of the I-vation(TM) Intravitreal Implant with triamcinolone acetonide (TA) in patients with Diabetic Macular Edema (DME) under an Investigational New Drug application with the U.S. Food and Drug Administration.

Field of Use
Field shall mean the treatment and/or prevention of any ocular disorder, including without limitation, diabetic macular edema (DME) and age related macular degeneration (AMD).

IPSCIO Record ID: 256301

License Grant
Australian Licensor grants
— an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Technology, the Licensor Program Technology, and the Licensor Confidential Information and
— an exclusive, even as to Licensor, royalty-bearing worldwide sublicense, with a right of further sublicense, under the Licensed University Technology, in each case to make, have made, use, sell or import Licensed Products, Devices and Formulations in the Territory in the Field; and,
—  an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Patent Rights, and the Licensor Program Patent Rights and
—  an exclusive, even as to Licensor, worldwide sublicense, with a right of further sublicense, under the Licensed University Patent Rights, in each case to make, have made, use, sell or import Licensed Products, Devices and Formulations in the Territory in the Field; and,
—  a non-exclusive sublicense, without a right to further sublicense, to use the Licensor Trademarks with the Licensed Products, Devices and Formulations in the Territory in the Field.
License Property
Licensor owns or otherwise controls certain patents, patent applications, technology, know-how and scientific and technical information relating to formulations for drug delivery and compatible devices, including Medidurâ„¢.

Licensor has extensive expertise in designing and developing innovative ophthalmic drug delivery systems.

Medidur is a tiny injectable, non-erodible, intravitreal device for the treatment of Diabetic Macular Edema (DME), which can lead to blindness. The implant is injected into the back of the eye in an office setting rather than a surgical one. It releases a constant amount of drug and lasts between 18 to 36 months.

Field of Use
The Field means the delivery of formulations for the treatment, control or prevention of any ophthalmic diseases and conditions in humans or animals.

The Licensee's Compound means any composition of matter, including, small and large molecules, therapeutic proteins, polynucleotides, both double-stranded and singlestranded, and antibodies, or biosimilars.

Collaborative research and license agreement is for Licensor’s controlled drug delivery technologies, including the MedidurTM technology, in ophthalmic applications.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.